An interventional study of HIFEM (HIGH INTENSITY FOCUSED ELECTROMAGNETIC) BTL EMSELLA in Pelvic Floor Muscle Dysfunction, sponsored by Institut Investigacio Sanitaria Pere Virgili. Recruiting at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by Institut Investigacio Sanitaria Pere Virgili · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Sprains and Strains with a site in Spain — 3 open to participants now, 3 under way, none of them phase 3. Sprains and Strains · Spain.
Among the 11 studies in Sprains and Strains with a site in Spain, this one is one of 2 that started in 2026, is one of 8 with no phase, and was the 10th registered.
246 studies on the registry are indexed under Sprains and Strains; 49 are open to participants now.
Browse Sprains and Strains studies →3 of the 11 studies in Sprains and Strains with a site in Spain are open now. Recruiting first, the newest first:
University of Cyprus · Sites in Spain, Greece
Ages 18–65 · Healthy volunteers
Hospital Universitario Infanta Leonor · Sites in Spain
Ages 5–16
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 36 Sprains and Strains studies recruiting now, 13 (36%) set no upper age limit and 20 (56%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 60 is close to the median of 60 across 162 interventional studies indexed under Sprains and Strains.
Median enrollment 88 across the 8 interventional studies, 150 across the 3 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 10 most frequent:
Institut Investigacio Sanitaria Pere Virgili is the lead sponsor of 39 studies on the registry; 17 are open to participants now.
Institut Investigacio Sanitaria Pere Virgili has 1 study filed under Sprains and Strains — fewer than ten, so there is no comparison to draw.
1 of the studies in Sprains and Strains with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07634952University of CyprusMitigation of Health Effects in Outdoor Workers by Reducing Exposure to Heat and Air Pollution | 2027-07-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Sprains and Strains with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this non-randomized community clinical trial is to test how effective HIFEM (High Intensity Focused Electromagnetic) technology (BTL Emsella) is in strengthening pelvic floor muscles. The study focuses on first-time mothers who have recently given birth (postpartum) via vaginal delivery and are not showing symptoms of dysfunction.
The main question this study aims to answer is:
- Can pelvic floor strength be restored after being exposed to weakening risk factors like pregnancy and childbirth?
How to study works; The researcher will compare two groups of women to see how their muscles recover:
Participant Journey:
BACKGROUND AND SCIENTIFIC RATIONALE The pelvic floor muscles (PFM) constitute a critical functional unit that frequently undergoes weakening due to cumulative risk factors over time. This degradation often leads to clinical conditions such as urinary incontinence (UI), sexual dysfunction, pelvic organ prolapse (POP), and other urogenital symptoms. Among these factors, pregnancy and childbirth (specifically vaginal delivery) are identified as the most significant contributors to PFM strength depletion. Scientific evidence indicates that mechanical trauma-such as levator ani tears, episiotomy, or the use of forceps-alongside increased intra-abdominal pressure during gestation and postpartum hormonal changes (including reduced collagen production), significantly compromise muscular tonicity and structural integrity.
TECHNOLOGY AND MECHANISM OF ACTION In 2018, the U.S. Food and Drug Administration (FDA) cleared the BTL EMSELLA device, utilizing High-Intensity Focused Electromagnetic (HIFEM) technology, for the treatment of urinary incontinence resulting from pelvic floor muscle weakness. Unlike conventional vaginal electrostimulation or voluntary Kegel exercises, HIFEM technology induces supramaximal muscle contractions, recruiting a higher percentage of muscle fibers than is physiologically possible through voluntary effort. This process promotes muscular hypertrophy, hyperplasia, increased vascularization, and neuromodulation. The stimulation is deep, homogeneous, and non-invasive, allowing for a painless, operator-independent treatment that can be performed while the patient remains fully clothed.
STUDY OBJETIVES AND HYPOTHESIS While current literature provides evidence of HIFEM efficacy in symptomatic women, there is a clinical interest in evaluating its preventive potential. Since pregnancy and childbirth are primary debilitating factors, this community-based clinical trial aims to evaluate the effectiveness of HIFEM technology as an early intervention in postpartum women who have been exposed to these risk factors for the first time but remain asymptomatic.
The study is designed to compare an experimental group receiving the HIFEM treatment protocol against a control group receiving standard care. The primary objective is to verify the efficacy of this technology in improving PFM tone and functional recovery in patients with muscle weakness prior to the onset of clinical symptoms. The investigator hypothesize that early application (recommended between 6 and 12 weeks postpartum) will result in a statistically significant improvement in muscle strength and a reduction in the long-term risk of urogenital dysfunction compared to the control group
METHODOLOGY Study Design This is a non-randomized, community-based clinical trial designed to compare two distinct cohorts. The Intervention Group will receive the treatment protocol utilizing High-Intensity Focused Electromagnetic (HIFEM) technology, while the Control Group will follow standard postpartum observation without the HIFEM intervention.
Setting The study will be conducted in specialized consultation health centers belonging to independently managed institutions within the public sector. Specifically, the clinical activities will take place at the Procrear Medical Centers located in Reus and Tarragona (Healthcare Center Code: E43924348).
Reference Population and Study Population The reference population consists of primiparous women from industrialized countries who have completed the postpartum period (quarantine) following a singleton vaginal delivery. The study population will include women attending the aforementioned medical centers who meet all eligibility criteria and provide informed consent to participate in the trial.
Sample Size and Statistical Power The required sample size is estimated at 30 participants. This calculation is based on accepting an alpha risk of 0.05 and a statistical power exceeding 0.80 in a two-sided contrast. The study aims to detect a statistically significant difference of 0.3 units or greater, assuming a common standard deviation of 0.55, based on the parameters established by Silantyeva E, et al. (Analysis of Posttreatment Data in Parous Women). To account for potential attrition, a follow-up loss rate of 10% has been integrated into the final recruitment target.
DATA COLLECTION AND INFORMATION SOURCES Recruitment and Informed Consent Potential participants attending the specialized pelvic floor units (Procrear Reus and Tarragona) will be screened for eligibility. Candidates will receive comprehensive verbal and written information regarding the study objectives, the HIFEM technology, and the clinical protocol. Participation is voluntary; eligible women will be invited to sign a specialized Informed Consent Form (ICF), which details both the device specifications and the study's privacy protocols. Participants may be self-referred or directed by other healthcare professionals during the pregnancy or postpartum period.
Study Group Allocation Following an initial clinical assessment of the pelvic floor and subsequent therapeutic recommendations, participants will personally elect their study arm. Those choosing to undergo immediate High-Intensity Focused Electromagnetic (HIFEM) therapy will constitute the Experimental Group, while those opting for a "wait-and-see" approach will form the Control Group. This non-randomized allocation respects the patient's clinical decision-making process in a private healthcare setting.
Clinical Assessment Timeline
To ensure data consistency, all physical examinations and functional assessments will be conducted by a single investigator (the Principal Investigator). The follow-up schedule is defined as follows:
Data Management and Confidentiality All clinical data will be recorded in the centers' proprietary electronic medical record (EMR) systems, which are managed by a specialized firm ensuring compliance with the General Data Protection Regulation (GDPR) and the Spanish Organic Law 3/2018. Access to these records is restricted via encrypted credentials. For the purpose of statistical analysis, data will be strictly pseudonymized using unique alphanumeric identification codes. Only the Principal Investigator (Lys Garcia Vilaplana) will hold the master key linking participant identities to their study codes.
Ethical Considerations The study guarantees absolute anonymity in any subsequent scientific communications or final reports. The Principal Investigator is the designated Data Controller, ensuring that the processing of personal data remains confidential and aligned with current digital rights and data protection legislation.
Intervention/Procedure Experimental Group: HIFEM Technology Protocol Participants electing the intervention will undergo a structured pelvic floor rehabilitation program using the BTL EMSELLA™, a device powered by patented High-Intensity Focused Electromagnetic (HIFEM) technology. The treatment is non-invasive and designed to stimulate the pelvic floor muscles (PFM) through supramaximal contractions.
Phase 1: Intensive Postpartum Recovery During the first two consecutive weeks, subjects will receive two sessions per week, with a minimum interval of 48 hours between treatments. Each session will last 20 minutes using the specialized "Postpartum" pre-set program. This specific configuration utilizes a shorter pulse interval (Tesla wave exposure) compared to standard protocols. The clinical rationale is to provide a higher density of stimulation to muscles recently weakened by pregnancy and childbirth, thereby accelerating functional recovery.
Phase 2: Consolidation and Maintenance Following the intensive phase, a two-week rest period will be observed to allow for muscular adaptation. Subsequently, participants will undergo a final two-week cycle consisting of two sessions per week. During this phase, a maintenance program with a longer interval between electromagnetic stimuli will be applied to reinforce the initial gains and stabilize muscle tone.
Treatment Administration and Positioning Each therapeutic session will be conducted with the participant seated at the center of the device's chair-like applicator. Proper ergonomic positioning is mandatory: feet must be flat on the floor, with a 90-degree angle at the knees and the thighs fully supported by the seat.
To ensure optimal PFM stimulation, the Principal Investigator (operator) will verify and adjust the patient's posture before and during each session. The intensity of the electromagnetic stimulus will be initiated at 0% and progressively titrated to the maximum level tolerated by the participant (up to 100%), ensuring the highest possible therapeutic recruitment of muscle fibers without causing discomfor
STATISCAL ANALYSIS PLAN Data Extraction and Masking Study data will be extracted from the centralized database and pseudonymized. Allocation masking will be implemented to ensure that the personnel responsible for the statistical analysis remain blinded to the group assignments, thereby minimizing potential bias.
Baseline Comparability and Descriptive Analysis An initial analysis will be conducted to compare the intervention and control groups, evaluating their homogeneity and the similarity in the distribution of key variables at baseline. The proportion of participants lost to follow-up in each group will be quantified, and an assessment will be performed to determine if these losses are independent of the study intervention. Standard descriptive statistics will be employed to summarize the data: quantitative variables will be expressed as means and standard deviations, while qualitative variables will be presented as frequencies and proportions.
Inferential Statistics Baseline quantitative characteristics will be compared using the Student's t-test. For qualitative variables, Pearson's chi-square test will be utilized. Data will be analyzed and compared both at baseline and at the conclusion of the study period.
EFFECTIVENESS EVALUATION To assess the effectiveness of the HIFEM intervention, Odds Ratios (OR) will be calculated to determine the association between groups. Both crude and adjusted ORs will be estimated, accounting for clinically relevant covariates and any pertinent interactions between variables.
Software and Significance Level All statistical procedures will be performed using SPSS version 25.0 or later. A p-value of \<0.05 will be considered statistically significant for all tests.
ETHICAL CONSIDERATIONS Informed Consent and Participant Information All participants who agree to enroll in the study will be thoroughly informed about the trial's nature, its specific objectives, and all activities directly linked to their participation. Potential subjects will be provided with a Participant Information Sheet in written format, allowing sufficient time for review and discussion before being asked to sign the Informed Consent Form (ICF).
CONFIDENTIALITY AND DATA PROTECTION The study guarantees compliance with current legal frameworks to ensure the absolute confidentiality of participants. This protection covers everything from the execution phase to the publication of scientific results, restricting access to clinical information solely under the internal protocols of the Procrear Center.
ETHICS COMIITEE APPROVAL The study project has been formally reviewed, approved, and is currently supervised by the Ethics Committee for Clinical Research (CEIC) of the Pere Virgili Institute for Health Research (IISPV). All recommendations and requirements set forth by the committee have been fully integrated into the study protocol to ensure the highest ethical standards.
EXPECTED RESULTS The primary objective of this study is to generate robust scientific evidence regarding the use of High-Intensity Focused Electromagnetic (HIFEM) technology during the postpartum period and its impact on pelvic floor muscle (PFM) recovery. The investigators aim to demonstrate whether exposure to recognized risk factors significantly debilitates the pelvic floor and if targeted HIFEM intervention facilitates accelerated functional recovery.
Furthermore, this study will provide a unique comparison of muscular evolution within a population that remains underrepresented in current literature. Given that there are currently no published studies specifically evaluating the BTL EMSELLA™ device in asymptomatic women following pregnancy, the data generated may offer critical insights for health policy decision-making across various clinical and public health contexts.
APPLICABILITY AND POTENTIAL OF THE TREATMENT This clinical trial will evaluate the preventive efficacy of HIFEM technology in women exposed to high-risk factors (pregnancy and childbirth) before the manifestation of clinical symptoms. The resulting evidence has the potential to shift the focus toward the early prevention of pelvic floor dysfunctions rather than reactive treatment. While the majority of existing research focuses on symptomatic urinary incontinence, this study addresses a significant gap by focusing on asymptomatic postpartum women.
STUDY LIMITATIONS The study identifies a potential selection bias, as participants are volunteers from private clinics who may have higher motivation and resources than the general population. To mitigate this, researchers will perform a systematic comparative analysis to control for these confounding variables and ensure the study's validity.
TIMELINE AND WORK PLAN
The project follows a strategic operational plan organized into six key phases spanning from 2022 to the final dissemination of results:
Preparatory Phase (2022-2025): Includes the comprehensive literature review on HIFEM technology and the formal study design and protocol drafting.
Regulatory Phase (Dec 2024 - Feb 2026): Ethical oversight and official approval from the IISPV Ethics Committee.
Operational Phase (Apr 2026 - Dec 2026): Active recruitment, intervention, and participant follow-up.
Final Phase: Statistical data analysis followed by the dissemination of findings in peer-reviewed journals and congresses.
RELEVANT BIBLIOGRAPHY The study incorporates an extensive list of scientific articles and clinical trials focused on pelvic floor muscle (PFM) dysfunctions, functional assessment techniques, and the clinical application of electromagnetic stimulation in postpartum recovery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants meeting the inclusion criteria upon evaluation who consent to the use of Emsella HIFEM technology.
Device: HIFEM (HIGH INTENSITY FOCUSED ELECTROMAGNETIC) BTL EMSELLA
Participants meeting the inclusion criteria at baseline who opt out of the treatment. These individuals will undergo a follow-up evaluation after 3 months
Eight sessions twice weekly, with a two-week gap between the first and second blocks of four sessions
Puborectalis Muscle Strain
Measurement of the puborectalis muscle length (in centimeters) using transperineal ultrasound.
Time frame: At baseline assessment (post-quarantine) and at the 3-month follow-up, in both group
Pelvic Floor Muscle Pressure (Dynamometry)
Pelvic floor muscle strength will be quantified by measuring the pressure exerted in Newtons with a specialized vaginal dynamometer. Measurements will be recorded at rest and during active voluntary contraction, yielding two separate measurements, both of which will be recorded
Time frame: At baseline assessment (post-quarantine) and at the 3-month follow-up, in both group
Pelvic Floor Muscle Performance (PERFECT Scheme)
escription: Clinical assessment of muscle function using the PERFECT scheme, which is based on the Modified Oxford Scale (0-5). The evaluation includes: P (Power): Maximum contraction strength. E (Endurance): Duration of the contraction. R (Repetitions): Number of repetitions maintained at original power. F (Fast): Number of quick, 1-second contractions. ECT (Every Contraction Timed): Total timing of the performance
Time frame: At baseline assessment (post-quarantine) and at the 3-month follow-up, in both group
Participant Age
Age of the participant in years, calculated based on the date of birth provided at the time of enrollment
Time frame: Baseline (Day 1)
Body Weight
Measurement of the participant's height, recorded in centimeters (cm) using a professional stadiometer
Time frame: Baseline visit. Self-reported weight
Body Height
Measurement of the participant's height, recorded in meters (m)
Time frame: Baseline visit. Self-reported heigh
Body Mass Index (BMI)
Calculation of the body mass index derived from the weight (kg) and height (m) measurements \[Formula: weight (kg) / height (m)²\]
Time frame: Baseline (Day 1)
Gestational Age at Delivery
Total duration of the pregnancy recorded in weeks at the time of childbirth
Time frame: Data will be self-reported by the participant at the baseline visit.
Pregnancy Weight Gain
Total maternal weight increase during the pregnancy, measured in kilograms (kg)
Time frame: Data will be self-reported by the participant at the baseline visit
Newborn Birth Weight
The weight of the neonate at the time of delivery, recorded in grams (g)
Time frame: Data will be self-reported by the participant at the baseline visit
Mode of Vaginal Delivery
Categorization of the delivery process into two types: Spontaneous (Eutocic): Delivery without instrumental assistance. Instrumental: Delivery requiring the use of forceps, vacuum extractor, or spatula
Time frame: Data will be self-reported by the participant at the baseline visit
Perineal Outcome (Perineal Status)
Classification of the perineum condition after delivery, categorized as: Intact: No trauma to the perineal area. Tear: Spontaneous laceration (including grade/degree if applicable). Episiotomy: Surgical incision performed during the second stage of labor.
Time frame: Data will be self-reported by the participant at the baseline visit
Plan to share: No
Start is estimated for Apr 2026; primary completion for Jul 2026, 3 months later.
Of 80 non-industry interventional studies with no phase under Sprains and Strains, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 35. This study's planned 3 months is below that.
Counting every sponsor, half of 82 studies reached it within 12 months; a quarter within 4 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Investigacio Sanitaria Pere Virgili